Cholinesterase inhibitors

British Columbia Medical Journal

Volumn 53, Issue 8, 2011, Pages 404-408

  Lee, Philip E ^a   Hsiung, Ging Yuek Robin ^a   Seitz, Dallas ^b   Gill, Sudeep S ^c   Rochon, Paula A ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Providence Continuing Care Centre   (Canada)

^c St Mary's of the Lake Hospital   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053961904     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Alzheimer Society. Rising tide: The impact of dementia on Canadian Society. Acces - sed 14 June 2011. www.alzheimer.ca/english/rising_tide/rising_tide.htm.
2. Rabey JM, Neufeld MY, Treves TA, et al. Cognitive effects of scopolamine in dementia. J Neural Transm 1996;103: 873-881.
3. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheim - er's disease. Lancet. 1976;2(8000):1403-1403.
4. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10: 122-126.
5. Iversen SD. The pharmacology of memory. C R Acad Sci 1998;321:209-215.
6. Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000;55:1460-1467.
7. Hsiung GYR, Loy-English I. Currenttherapy: A review of the cholinesterase inhibitors. BCMJ 2004;46:338-343.
8. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A metaanalysis. CMAJ 2003;169:557-564.
9. Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004;12:358-369.
10. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of random - ised clinical trials. BMJ 2005;331:321-327.
11. J. Cholinesterase inhibitors for Alz - heimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
12. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD001190.
13. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;(1):CD001747.
14. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;(2): CD001191.
15. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric and functional impairment in Alzheimer disease. JAMA 2003;289:210-216.
16. Hogan DB, Goldlist B, Naglie G, et al. Comparison studies of cholinesterase inhibitors for Alzheimer's disease. Lancet Neurol 2004;3:622-626.
17. Health Canada. Donepezil (product monograph). Accessed 7 November 2010. http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=51492.
18. Health Canada. Rivastigmine (product monograph). Accessed 7 November 2010. http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=82234and http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=78817.
19. Health Canada. Galantamine (product monograph). Accessed 7 November 2010. http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=75213.
20. Rodda J, Walker Z. Ten years of cholin - esterase inhibitors. Int J Geriatr Psych 2009;24:437-442.
21. BC Ministry of Health. Alzheimer's Disease Therapy Initiative. Accessed 6 Nov ember 2010. www.health.gov.bc.ca/pharmacare/adti/index.html.
22. Feldman HF, Gauthier S, Hacker J, et al.; Donepezil MSAD Study Investigators Group. A 24-week, randomized, doubleblind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;28:613-620.
23. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-469.
24. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular de - mentia: A meta-analysis of randomis ed controlled trials. Lancet Neurol 2007;6: 782-792.
25. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359 (9314):1283-1290.
26. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2009;(3):CD006104.
27. Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials. PLoS Med 2007; 4:e338.
28. Maidment I, Fox C, Boustani M. Cholin - esterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006;(1):CD004747.
29. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003; (3):CD003672.
30. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;(2)CD003154.
31. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alz - heimer's disease: A meta-analysis of randomized clinical trials. Dement Geriatri Cogn Disord 2007;24:20-27.